Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis (Q39842246)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis (English)

1 reference

Europe PubMed Central

15 September 2017

Mycobacterium tuberculosis

0 references

Stefan Kaufmann

17

1 reference

Europe PubMed Central

15 September 2017

author name string

Ronggai Sun

1

1 reference

Europe PubMed Central

15 September 2017

Yasir A W Skeiky

2

1 reference

Europe PubMed Central

15 September 2017

Angelo Izzo

3

1 reference

Europe PubMed Central

15 September 2017

Veerabadran Dheenadhayalan

4

1 reference

Europe PubMed Central

15 September 2017

Zakaria Imam

5

1 reference

Europe PubMed Central

15 September 2017

Erica Penn

6

1 reference

Europe PubMed Central

15 September 2017

Katherine Stagliano

7

1 reference

Europe PubMed Central

15 September 2017

Scott Haddock

8

1 reference

Europe PubMed Central

15 September 2017

Stefanie Mueller

9

1 reference

Europe PubMed Central

15 September 2017

John Fulkerson

10

1 reference

Europe PubMed Central

15 September 2017

Charles Scanga

11

1 reference

Europe PubMed Central

15 September 2017

Ajay Grover

12

1 reference

Europe PubMed Central

15 September 2017

Steven C Derrick

13

1 reference

Europe PubMed Central

15 September 2017

Sheldon Morris

14

1 reference

Europe PubMed Central

15 September 2017

David M Hone

15

1 reference

Europe PubMed Central

15 September 2017

Marcus A Horwitz

16

1 reference

Europe PubMed Central

15 September 2017

Jerald C Sadoff

18

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

2 June 2009

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

27

1 reference

Europe PubMed Central

15 September 2017

33

1 reference

Europe PubMed Central

15 September 2017

4412-4423

1 reference

Europe PubMed Central

15 September 2017

In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The success and failure of BCG - implications for a novel tuberculosis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The SCID mouse mutant: definition, characterization, and potential uses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Genome plasticity of BCG and impact on vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Disseminated tuberculosis in interferon gamma gene-disrupted mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Genotype and age influence the effect of caloric intake on mortality in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Tuberculosis in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Conversion of an extracellular cytolysin into a phagosome-specific lysin which supports the growth of an intracellular pathogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

How can immunology contribute to the control of tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Global Epidemiology of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Immunity to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Advances in tuberculosis vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.05.048

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39842246&oldid=2139383395"